Passage Bio Inc. - PASG Total Company Value-to-Revenue Ratio

CNS treatment patents create a defensive barrier, which is confirmed by the current valuation of Passage Bio, Inc. (PASG) relative to revenue. Price growth is based on unique DNA delivery methods to the brain and a high capital-intensive barrier to entry. Diversification of early-stage orphan research reduces regulatory risks, while 0.00 represents the current metric value.
PASG (Passage Bio Inc.): analytical breakdowns and indicator data

This indicator compares Enterprise Value (EV) to annual revenue, allowing for an assessment of the company's market value regardless of its debt load. The EV/Sales multiple trend reflects the speculative expectations of investors, which for Passage Bio, Inc. (PASG) are critically dependent on the success of a single gene platform amid a narrow market and high clinical risks.